Obesity, GLP-1s and Dermatology

GLP-1 receptor agonists offer potential therapeutic benefits for inflammatory skin conditions, including psoriasis and hidradenitis suppurativa (HS), by modulating systemic inflammation and metabolic syndrome. Adipokines like leptin and TNF-alpha, produced by fat cells, directly drive inflammatory pathways in these diseases. While large-scale cohort studies suggest significant reductions in mortality, cardiovascular events, and surgical interventions for HS patients on GLP-1s, the reliance on database-driven data raises questions about causality and the independence of these effects from weight loss. Clinicians remain cautious about prescribing these agents within dermatology, emphasizing the need for prospective controlled trials to clarify whether GLP-1s provide direct anti-inflammatory relief or merely address underlying obesity. Practical challenges, such as managing side effects like delayed gastric emptying and coordinating care with primary providers, remain central to the clinical integration of these metabolic therapies in dermatological practice.